Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us ![]()
About
PEGS Boston SummitPEGS Boston Summit
Not Confirmed
Not Confirmed
11 May-15 November, 2026
Not Confirmed
Not Confirmed
07-10 June, 2026
Not Confirmed
Not Confirmed
09-11 June, 2026
List your booth number for exhibitions, ask us
CONTACT DETAILS






Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
PEGS Boston SummitPEGS Boston Summit
Industry Trade Show
Not Confirmed
11 May-15 November, 2026
Industry Trade Show
Not Confirmed
07-10 June, 2026
Industry Trade Show
Not Confirmed
09-11 June, 2026
Digital content

07 Jun 2026
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/ascletis-reinforces-its-differentiated-obesity-portfolio-at-american-diabetes-association-ada-2026-scientific-sessions-showcasing-asc30-clinical-data-and-exciting-preclinical-findings-from-asc37-and-asc39-302793255.html

07 Apr 2026
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/ascletis-announces-fixed-dose-combination-of-asc30-once-daily-oral-small-molecule-glp-1r-agonist-and-asc39-once-daily-oral-small-molecule-amylin-selective-amylin-receptor-agonist-for-clinical-development-302735615.html

17 Mar 2026
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/oral-small-molecule-amylin-receptor-agonist-asc39-demonstrated-eloralintide-like-amylin-selectivity-and-efficacy-in-preclinical-models-302715843.html

10 Mar 2026
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/ascletis-announces-positive-topline-results-from-us-phase-ii-24-week-study-for-its-ultra-long-acting-subcutaneous-depot-formulations-of-small-molecule-glp-1r-agonist-asc30-for-obesity-302709245.html

10 Mar 2026
// FIERCE BIOTECH
https://www.fiercebiotech.com/biotech/ascletis-posts-phase-2-obesity-data-touts-potential-quarterly-glp-1-dosing

10 Feb 2026
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/ascletis-selects-oral-amylin-receptor-peptide-agonist-asc36-for-clinical-development-302683756.html
ABOUT THIS PAGE